{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:26:17Z","timestamp":1792499177293,"version":"4.5.0"},"reference-count":26,"publisher":"Medical Association of Nippon Medical School","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2022,4,25]]},"DOI":"10.1272\/jnms.jnms.2022_89-222","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T22:12:13Z","timestamp":1637878333000},"page":"139-144","source":"Crossref","is-referenced-by-count":14,"title":["Role of Kampo Medicine in Modern Cancer Therapy: Towards Completion of Standard Treatment"],"prefix":"10.1272","volume":"89","author":[{"given":"Yoshiharu","family":"Motoo","sequence":"first","affiliation":[{"name":"Departments of Medical Oncology and Kampo Medicine, Komatsu Sophia Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Motoo Y, Seki T, Tsutani K. Traditional Japanese medicine, Kampo: its history and current status. Chin J Integr Med. 2011 Feb;17 (2):85-7. doi: 10.1007\/s11655-011-0653-y. PubMed PMID: 21390572.","DOI":"10.1007\/s11655-011-0653-y"},{"key":"2","unstructured":"2. Japan Kampo Medicines Manufactures Association. The Future Vision for Kampo Medicines 2040 - Responsibility for People&apos;s Health and Healthcare - [Internet]. Available from: https:\/\/www.nikkankyo.org\/jkma_guide\/english_guide\/english4.htm"},{"key":"3","unstructured":"3. Study Group of Japanese Association for Supportive Care in Cancer, editor. Kampo Katsuyo Gaido [Practical Guide of Kampo for Cancer Supportive Care]: Nanzando; 2020. Japanese."},{"key":"4","unstructured":"4. Cancer Control Council. Gan taisaku kasokuka puran heno teigen [Proposals to the basic plan to promote cancer control programs] [Internet]. Available from: https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-10904750-Kenkoukyoku-Gantaisakukenkouzoushinka\/0000106059.pdf Japanese."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Motoo Y, Arai I, Kogure T, Tsutani K. Review of the first 20 years of the Evidence-Based Medicine Committee of the Japan Society for Oriental Medicine. Trad Kampo Med. 2021 March 30.","DOI":"10.1002\/tkm2.1279"},{"key":"6","unstructured":"6. Evidence-Based Medicine Committee of Japan Society for Oriental Medicine. Evidence Reports of Kampo Treatment 2019 [Internet]. Available from: http:\/\/www.jsom.or.jp\/medical\/ebm\/ Japanese."},{"key":"7","unstructured":"7. Hinohara S. Kampo ni tsuite [About Kampo Medicine]. In: Dakara Igakuwa Omoshiroi [Therefore, medicine is interesting]: Nihon Iji Shimpo [Japan Medical Journal]; 2014. p. 10. Japanese."},{"key":"8","unstructured":"8. National Cancer Institute. Dictionary of Cancer Terms. Supportive care [Internet]. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/supportive-care"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2003 May;51 (5):403-6. doi: 10.1007\/s00280-003-0585-0","DOI":"10.1007\/s00280-003-0585-0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Matsuda C, Munemoto Y, Mishima H, et al. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol. 2015 Jul;76 (1):97-103.","DOI":"10.1007\/s00280-015-2767-y"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kaku H, Kumagai S, Onoue H, et al. Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel\/carboplatin therapy: A multicenter collaborative study. Exp Ther Med. 2012 Jan;3 (1):60-5.","DOI":"10.3892\/etm.2011.375"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Abe H, Kawai Y, Mori T, et al. The Kampo medicine goshajinkigan prevents neuropathy in breast cancer patients treated with docetaxel. Asian Pac J Cancer Prevent. 2013;14 (11):6351-6.","DOI":"10.7314\/APJCP.2013.14.11.6351"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kono T, Mamiya N, Chisato N, et al. Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Complement Alternat Med. 2011;2011:418481.","DOI":"10.1093\/ecam\/nep200"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nishioka M, Shimada M, Kurita N, et al. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol. 2011 Aug;16 (4):322-7.","DOI":"10.1007\/s10147-010-0183-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kono T, Hata T, Morita S, et al. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. Cancer Chemother Pharmacol. 2013;72 (6):1283-90.","DOI":"10.1007\/s00280-013-2306-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Oki E, Emi Y, Kojima H, et al. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol. 2015;20 (4):767-75.","DOI":"10.1007\/s10147-015-0784-9"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kuriyama A, Endo K. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Support Care Cancer. 2018;26 (4):1051-9.","DOI":"10.1007\/s00520-017-4028-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hoshino N, Ganeko R, Hida K, Sakai Y. Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Int J Clin Oncol. 2018;23 (3):434-42.","DOI":"10.1007\/s10147-017-1229-4"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Motoo Y, Tomita Y, Fujita H. Prophylactic efficacy of ninjin&apos;yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2). Int J Clin Oncol. 2020;25 (6):1123-9.","DOI":"10.1007\/s10147-020-01648-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yoshida T, Sawa T, Ishiguro T, Horiba A, Minatoguchi S, Fujiwara H. The efficacy of prophylactic Shakuyaku-Kanzo-to for myalgia and arthralgia following carboplatin and paclitaxel combination chemotherapy for non-small cell lung cancer. Support Care Cancer. 2009;17 (3):315-20.","DOI":"10.1007\/s00520-008-0508-z"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Jeong JS, Ryu BH, Kim JS, et al. Bojungikki-tang for cancer-related fatigue: a pilot randomized clinical trial. Integr Cancer Ther. 2010;9 (4):331-8.","DOI":"10.1177\/1534735410383170"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Barton DL, Liu H, Dakhil SR, et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105 (16):1230-8.","DOI":"10.1093\/jnci\/djt181"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Takeda H, Nakagawa K, Okubo N, et al. Pathophysiologic basis of anorexia: focus on the interaction between ghrelin dynamics and the serotonergic system. Biol Pharm Bull. 2013;36 (9):1401-5.","DOI":"10.1248\/bpb.b13-00364"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Yakabi K, Kurosawa S, Tamai M, et al. Rikkunshito and 5-HT2C receptor antagonist improve cisplatin-induced anorexia via hypothalamic ghrelin interaction. Regul Pept. 2010;161 (1-3):97-105.","DOI":"10.1016\/j.regpep.2010.02.003"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ohno T, Yanai M, Ando H, et al. Rikkunshito, a traditional Japanese medicine, suppresses cisplatin-induced anorexia in humans. Clin Exp Gastroenterol. 2011;4:291-6.","DOI":"10.2147\/CEG.S26297"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Yoshiya T, Mimae T, Ito M, et al. Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy. Invest New Drugs. 2020;38 (2):485-92.","DOI":"10.1007\/s10637-019-00836-x"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/89\/2\/89_JNMS.2022_89-222\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T04:16:18Z","timestamp":1652501778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/89\/2\/89_JNMS.2022_89-222\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2022_89-222","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"article-number":"JNMS.2022_89-222"}}